Literature DB >> 34985731

Landmark Series: Importance of Pancreatic Resection Margins.

Mihir M Shah1, Jashodeep Datta2, Nipun B Merchant2, David A Kooby3.   

Abstract

An important goal of cancer surgery is to achieve negative surgical margins and remove all disease completely. For pancreatic neoplasms, microscopic margins may remain positive despite gross removal of the palpable mass, and surgeons must then consider extending resection, even to the point of completion pancreatectomy, an option that renders the patient with significant adverse effects related to exocrine and endocrine insufficiency. Counterintuitively, extending resection to ensure clear margins may not improve patient outcome. Furthermore, the goal of improving survival by extending the resection may not be achieved, as an initial positive margin may indicate more aggressive underlying tumor biology. There is a growing body of literature on this topic, and this landmark series review will examine the key publications that guide our management for resection of pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasms, and pancreatic neuroendocrine tumors.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2022        PMID: 34985731     DOI: 10.1245/s10434-021-11168-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  58 in total

1.  Whipple made simple for surgical pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors.

Authors:  N Volkan Adsay; Olca Basturk; Burcu Saka; Pelin Bagci; Denizhan Ozdemir; Serdar Balci; Juan M Sarmiento; David A Kooby; Charles Staley; Shishir K Maithel; Rhonda Everett; Jeanette D Cheng; Duangpeng Thirabanjasak; Donald W Weaver
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

2.  Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma.

Authors:  Nigel B Jamieson; Alan K Foulis; Karin A Oien; James J Going; Paul Glen; Euan J Dickson; Clem W Imrie; Colin J McKay; Ross Carter
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

3.  Pancreatic cancer surgery in the new millennium: better prediction of outcome.

Authors:  Werner Hartwig; Thilo Hackert; Ulf Hinz; Alexander Gluth; Frank Bergmann; Oliver Strobel; Markus W Büchler; Jens Werner
Journal:  Ann Surg       Date:  2011-08       Impact factor: 12.969

Review 4.  Pancreatic cancer: clinical presentation, pitfalls and early clues.

Authors:  E P DiMagno
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

5.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Authors:  John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler
Journal:  Lancet       Date:  2017-01-25       Impact factor: 79.321

Review 6.  Early diagnosis of pancreatic cancer: challenges and new developments.

Authors:  Sukhwinder Kaur; Michael J Baine; Maneesh Jain; Aaron R Sasson; Surinder K Batra
Journal:  Biomark Med       Date:  2012-10       Impact factor: 2.851

Review 7.  Perspectives in the treatment of pancreatic adenocarcinoma.

Authors:  Angel Cid-Arregui; Victoria Juarez
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

8.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Authors:  Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin.

Authors:  Fiona Campbell; Richard A Smith; Philip Whelan; Robert Sutton; Michael Raraty; John P Neoptolemos; Paula Ghaneh
Journal:  Histopathology       Date:  2009-09       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.